SCHW — The Charles Schwab Corporation

Sentiment is genuinely split, which is why it lands Neutral rather than on one side. The sell-side is still constructive - 20 analysts, consensus rating Buy, 29 buy vs. 19 hold vs. 3 sell, and a $119.80 average price target - but targets are being walked down post-print (Goldman trimmed $122 to $117, Truist cut to $112). The tape tells a harsher story: as of 2026-10-16 the shares were 10.7% lower over one month, 7.5% lower over three months, RSI at 31.4, and the stock trading below the LOWEST analyst target ($95). The reason is the guidance nuance: Q3 2026 NIM of 3.04% and $190.4B of core net new assets (5.8% annualized organic growth, 1.2M new brokerage accounts) were strong, but client bank deposits fell ~2% sequentially to $244B and management put full-year revenue growth and NIM at the low end of guidance. Investors read that as 'the recovery is peaking,' and sold.

This is a clean, multi-year cyclical recovery that has just started to mature. Q4 2023 was the trough of the rate-shock/cash-sorting period: revenue $6.29B, operating income $1.19B (19.0% margin), diluted EPS $0.51. Eleven quarters later, Q3 2026 shows revenue of $8.17B, operating income of $3.78B (46.2% margin, an all-time high in this series), and EPS of $1.62 - up 218% from the trough. The trajectory: operating margin climbed 19.0% (Q4'23) to 36.9% (Q1'25) to 42.9% (Q3'25) to 46.2% (Q3'26). YoY revenue growth accelerated through 2026 (+7.8% Q4'25, +9.8% Q1'26, +25.0% Q2'26, +16.0% Q3'26) and YoY EPS growth ran +41.5%, +38.4%, +42.6%, then +28.6% in the latest quarter. Two cautions. First, both revenue and EPS growth decelerated in Q3 2026 versus Q2 - that is a real inflection at the margin, not noise, and it lines up with the guidance trim. Second, Q2 2026 revenue of $8.52B is an unexplained +16.7% sequential jump that Q3 2026 then gave back (-4.1%), and the FMP revenue series sits roughly $1B/quarter above the 'net revenue' figure the company reported in the Q3 2026 release (~$7.17B, +16.9% YoY). Treat absolute revenue levels as approximate; the direction of travel is consistent in both datasets. Data quality note: the latest balance sheet line is corrupted (equity shown as $3.1B vs. $49.9B at 2026-06-30; total assets $4.1B vs. $517.3B) and Q3 2026 OCF/FCF are recorded as zero. That artifact distorts the deterministic score, as discussed below.

Cheap versus its own history, roughly fair-to-modestly-cheap on normalized forward numbers. As of 2026-10-16 at $93.84: trailing P/E of 15.9x against a five-year average of 25.3x (a ~37% discount), P/S of 5.21x against a five-year average of 6.38x, and a forward P/E of 14.5x on the $6.461 FY2027 consensus EPS. The reported P/B of 52.3x is garbage - it is derived from that corrupted $3.1B equity figure; using the last clean equity number ($49.88B at 2026-06-30) P/B is roughly 3.3x. The catch is that the 0.424 TTM PEG ratio flatters the stock: on forward numbers, consensus FY2027 EPS of $6.461 is only about 5-10% above trailing EPS of $5.86-$6.16, so the 'growth' leg of the PEG largely reflects growth that has already happened. Verdict: you are paying about 14.5x for a business that just grew revenue 16% and earns a 46% operating margin, which is undemanding - but the discount to its own history is compensation for NIM durability risk and a shrinking deposit base, not a free lunch.

The stock is trading below the lowest analyst target in the book ($95) despite an EPS beat, which tells you most of the near-term bad news is already in the price - what is NOT priced is upside to estimates. Consensus FY2027 EPS of $6.461 essentially just annualizes the current quarter ($1.62 x 4 = $6.48), i.e., the street is modeling flat earnings. So the asymmetry works both ways. Bear case: if the Fed eases faster than modeled, NIM slides below 3.00%, the deposit base keeps leaking, and you get a repeat of 2023-2024 - a 'cheap' multiple expanding on falling EPS. Bull case: cash sorting normalizes, NIM works toward the top of the 3.00-3.10% band, and EPS runs to $6.80-$7.00; at 17-18x that is $116-$126, roughly in line with or above consensus. Watch two prints: whether the $244B deposit line stabilizes, and whether NIM stays at or above 3.04%. Those two numbers, not the headline EPS beat, decide which path this takes.

Bearish tape, oversold but not washed out. As of 2026-10-16, RSI(14) stood at 31.35 - just above the classic 30 oversold line - with the stock 4.0% below its 20-day SMA, 10.1% below its 50-day SMA, and 4.3% below its 200-day SMA, i.e., below all three. The distribution of returns matters here: -2.8% over one week, -10.7% over one month, -7.5% over three months, but +1.8% over six months. That is a sharp one-month repricing rather than a year-long downtrend, which usually means momentum traders should stay patient while longer-horizon buyers get an improving entry. Practical read: no technical confirmation of a bottom until the stock reclaims the 50-day (a long way up, around the $104 area) - the reference levels below are the $95 low analyst target, then the 52-week low of $83.96. Buying into RSI ~31 in a name below its 50-day has historically been a tactical trade, not a trend call.

• Fed policy path is the dominant swing factor: NIM hit 3.04% in Q3 2026 (up from 2.88% a year earlier), but management now guides NIM expansion to the low end of its 3.00%-3.10% range, so faster rate cuts would compress asset yields faster than deposit costs reset.
• Cash sorting has not fully run its course - total client bank deposits slipped roughly 2% sequentially to $244B as clients rotated into higher-yielding alternatives, forcing Schwab to lean on wholesale funding that caps how fast margin can expand even as margin balances ($187.9B) and bank loans ($72.3B) grow.
• A thin equity cushion for a $517B balance sheet: $49.9B of stockholders' equity at 2026-06-30 leaves less room for the aggressive buybacks that have been flattering EPS growth than the market seems to assume.
• Capital-markets sensitivity is direct - margin balances, trading activity and asset management fees all ladder off investor risk appetite, so an equity drawdown hits revenue on multiple lines at once despite the 0.78 beta.
• Structural fee and competitive pressure plus the product ramp (AI advisor tools, added crypto support for Solana, Avalanche and Chainlink) will determine whether record asset gathering converts into revenue per account or just into accounts.

• Q4 2026 earnings on 2027-01-20 (estimated) - the single most important datapoint is whether NIM holds near 3.04% and whether the $244B deposit base stops shrinking.
• Normalization of cash sorting; outright stabilization in client bank deposits would remove the biggest structural overhang on NIM and on the operating-leverage story.
• Any upward revision to the $6.461 FY2027 consensus EPS - the estimate implies roughly flat-to-low-single-digit growth, so even a modest beat would re-rate the forward multiple.
• Continued asset-gathering momentum: $190.4B of core net new assets in Q3 2026 (5.8% annualized organic growth) and 1.2M new brokerage accounts, if sustained, compound the revenue base independent of rates.
• Product and tech rollouts - AI tools for advisors and self-directed clients, plus broader crypto support - that could lift engagement and revenue per account.

• NIM compression if the Fed eases faster than modeled - management already flagged full-year 2026 revenue growth and NIM tracking to the low end of guidance ranges, and a deposit base that shrinks 2% a quarter makes the funding mix worse, not better.
• The recovery is maturing: consensus FY2027 EPS of $6.461 is barely above trailing EPS, so the market is being asked to pay up for a cyclical upcycle that is largely already in the reported numbers.
• Deposit attrition into higher-yielding alternatives forcing more expensive wholesale funding, which would blunt the ~800bps of operating leverage management is guiding to.
• Distorted and thin balance-sheet optics - the reported 52.3x P/B is nonsense (an artifact of a Q3 2026 equity line of $3.1B versus $49.9B three months earlier), but even the clean ~3.3x P/B sits on a low equity base for a $517B balance sheet, leaving limited flexibility in a credit or funding shock.
• Correlated rate exposure: a bear market would simultaneously pressure margin balances, asset management fees and client cash deployment, so the low beta does not insulate revenue.

Schwab is a high-quality franchise in the late innings of a real cyclical recovery, not a structurally broken business - revenue up 16% YoY, operating margin at a series high of 46.2%, 5.8% annualized organic asset growth, and the stock at 15.9x trailing / 14.5x forward earnings against a 25.3x five-year average. But the easy money has been made: management just guided to the low end, deposits are shrinking, and the street models essentially flat FY2027 EPS, which is why the shares sit 10% below the 50-day and under every published target. At $93.84 this is a reasonable risk/reward for a patient holder with a multi-quarter horizon and a clear thesis on NIM and deposits - it is not a screaming bargain, and the next two quarterly prints decide whether this is a value stock or a value trap.

Justified-P/E method: 18.0x applied to FY2027 consensus EPS of $6.461 = $116, cross-checked against the stock's own multiple history (25.25x five-year average, ~18-20x pre-2020 norm, 14.5x current forward) and against a low-beta (0.78) franchise earning ~18% ROE. The 18x multiple is deliberately below the five-year average because the zero-rate deposit-franchise premium of 2020-2021 is gone and consensus models flat-to-low-single-digit FY2027 EPS growth; it is a premium to today's 14.5x because 5.8% annualized organic asset growth and a 46% operating margin are worth more than a trough multiple, and the ~24% upside to that figure roughly brackets the $95-$145 sell-side range.